📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-29 15:15
130 analysed today
FollowTelegram
130
Today
151,574
All-time analysed
43,443
Positive
6,735
Negative
92,579
Neutral
8,749
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
9 announcements match the current filters (relevance ≥ 5).
HOMRE AGM Approves ₹12.50 Cr Preferential Warrants and 3 Cr ESOP Scheme
HOMRE Ltd submitted clarified proceedings of its 36th AGM held on September 24, 2026, following an initial reporting delay flagged by BSE. Shareholders approved the issuance of 5,41,12,552 fully convertible warrants at ₹2.31 per warrant on a preferential basis, raising ₹12.50 crore. This fundraise represents approximately 30% of the company's current market capitalization of ₹42 crore. Additionally, shareholders approved the HOMRE ESOP 2026 scheme comprising up to 3 crore options.
Confidence: HIGH
What changedHOMRE Ltd submitted a clarification regarding delayed submission alongside the detailed 36th AGM proceedings where all resolutions were approved.
Why it mattersThe approval of ₹12.50 crore in convertible warrants provides growth capital relative to HOMRE's ₹11 crore net worth, but brings future equity dilution.
Warrant issue value: ₹12,49,99,997Warrant issue price: ₹2.31 per warrantNumber of warrants: 5,41,12,552ESOP options approved: 3,00,00,000Warrants value vs Market Cap: ~29.8%
📅 Short termExchanges are likely to take the clarification on record without material impact, while markets digest the equity dilution terms.
📈 Long termIf successfully converted, the ₹12.50 crore capital infusion could strengthen HOMRE's ₹11 crore net worth and support expansion in its jewellery business.
⚠ Risk flags
- Substantial equity dilution potential from 5.41 crore warrants and 3 crore ESOP options
- Procedural compliance delay flagged by stock exchange
Key Highlights
Approved issuance of 5,41,12,552 fully convertible warrants at ₹2.31 each, aggregating to ₹12,49,99,997
Fundraise of ₹12.50 crore equals ~30% of current market cap of ₹42 crore
Approved HOMRE ESOP 2026 plan allowing up to 3,00,00,000 equity stock options
AGM attended by 66 members including 5 promoter shareholders
Delay in uploading AGM proceedings on September 24 resolved by filing on September 25 at 6:10:48 PM
👀 What to Watch
Track the formal scrutinizer voting report and subsequent allotment disclosures for the ₹12.50 crore convertible warrants, along with their dilution effect on existing equity.
HOMRE AGM Approves ₹12.5 Cr Convertible Warrants Issue and 3 Cr ESOP Pool
HOMRE Limited shareholders approved all resolutions at its 36th AGM held on September 24, 2026, with requisite majority. The most significant resolution is the preferential issue of 5,41,12,552 fully convertible warrants at ₹2.31 each, raising approximately ₹12.50 crore. This fundraise represents nearly 30% of the company's current market cap of ₹42 crore and roughly 46% of its TTM revenue of ₹27 crore. Additionally, shareholders approved the HOMRE ESOP 2026 pool of up to 3 crore options and regularized several board appointments.
Confidence: HIGH
What changedShareholders officially approved a ₹12.50 crore preferential warrant issue, an employee stock option scheme of 3 crore options, and board appointments.
Why it mattersThe ₹12.50 crore capital infusion significantly strengthens the balance sheet (net worth currently ₹11 crore), though conversion of warrants will lead to sizable equity dilution.
Preferential Warrants Issue Value: ₹12,49,99,997Number of Convertible Warrants: 5,41,12,552Issue Price per Warrant: ₹2.31Fundraise vs Market Cap: ~29.8%ESOP Pool Size: 3,00,00,000 options
📅 Short termReceipt of application money for the preferential warrants and filing of voting results on BSE.
📈 Long termThe capital will support working capital and business expansion, but full conversion of warrants and ESOPs will cause substantial equity base expansion and dilution.
⚠ Risk flags
- Significant potential equity dilution from 5.41 crore warrants and 3.0 crore ESOP options against a micro-cap base
- Deployment and execution risk on the incoming funds
Key Highlights
Approved issuance of 5,41,12,552 fully convertible warrants at ₹2.31 per warrant on a preferential basis
Total preferential issue proceeds aggregate to ₹12,49,99,997 (approx. ₹12.5 crore)
Approved HOMRE ESOP 2026 scheme comprising up to 3,00,00,000 equity options of face value ₹1 each
66 members, including 5 promoter shareholders, attended the AGM through video conferencing
👀 What to Watch
Track the formal allotment of warrants and the timeline for cash inflow, as well as the detailed voting results scrutinizer report expected within two working days.
HOMRE AGM Considers ₹12.5 Cr Preferential Warrants and 3 Cr ESOP Scheme
HOMRE Limited concluded its 36th Annual General Meeting on September 24, 2026. Shareholders deliberated on key special business items including the issuance of 5,41,12,552 fully convertible warrants at ₹2.31 each, raising ₹12.50 crore on a preferential basis. This proposed fundraise represents approximately 30% of the company's current market cap of ₹42 crore. In addition, the AGM considered the HOMRE ESOP 2026 scheme granting up to 3 crore options, alongside regularisation of board appointments.
Confidence: HIGH
What changedShareholders at the 36th AGM considered resolutions to issue ₹12.5 crore in convertible warrants and establish a 3 crore share ESOP plan.
Why it mattersA ₹12.50 crore capital infusion represents substantial fresh equity relative to HOMRE's ₹11 crore net worth, though it carries potential equity dilution from both warrants and the ESOP pool.
Warrant issue value: ₹12,49,99,997Issue price per warrant: ₹2.31Number of warrants: 5,41,12,552ESOP pool size: 3,00,00,000 optionsFundraise vs Market Cap: ~29.8%
📅 Short termFocus remains on the voting results filing to verify whether the preferential issue and board changes were passed by shareholders.
📈 Long termIf approved, the ₹12.5 crore warrant proceeds will more than double the net worth, providing growth capital for its gems and jewellery operations, albeit with significant equity dilution.
⚠ Risk flags
- Dilution risk from 5.41 crore warrants and 3.0 crore ESOP options against a micro-cap equity base
- High historical valuation multiple (P/E 154.2) relative to slim operating margins
Key Highlights
Proposed preferential issue of 5,41,12,552 convertible warrants at ₹2.31 each to raise ₹12,49,99,997
Approval sought for HOMRE ESOP 2026 pool of up to 3,00,00,000 equity options
Proposed warrant issue of ₹12.50 crore is nearly 30% of the current market capitalization of ₹42 crore
AGM held on September 24, 2026 with e-voting concluded on September 23, 2026 and during the meeting
👀 What to Watch
Track the upcoming disclosure of voting results and scrutinizer report to confirm shareholder approval of the warrant issuance and ESOP scheme.
HOMRE Ltd sets floor price at ₹2.31 for proposed ₹12.50 Cr preferential warrant issue
HOMRE Ltd has determined a floor price of ₹2.31 per warrant for its proposed preferential issue of up to 5,41,12,553 fully convertible warrants. The total proposed fundraise amounts to ₹12,49,99,997 (~₹12.50 Cr), representing approximately 28.4% of the company's current market capitalization of ₹44 Cr. Each warrant is convertible into one equity share of face value ₹1 each. The Relevant Date for determining the minimum pricing under SEBI ICDR Regulations was August 25, 2026.
Confidence: HIGH
What changedThe company fixed the floor price at ₹2.31 per warrant and specified terms to issue 5.41 Cr warrants to raise ~₹12.50 Cr.
Why it mattersThe ₹12.50 Cr capital infusion represents ~28.4% of the current market cap and ~46.3% of TTM revenue, providing critical growth capital to strengthen a company currently having low net worth.
Floor price per warrant: ₹2.31Total warrants proposed: 5,41,12,553Total issue size: ₹12,49,99,997Fundraise vs Market Cap: ~28.4%Relevant Date: 25 August 2026
📅 Short termThe floor price of ₹2.31 is at a premium to the current market price of ₹1.90, which may provide positive sentiment.
📈 Long termSuccessful capital infusion can improve the balance sheet and scale operations, offset by equity dilution upon full warrant conversion.
⚠ Risk flags
- Equity dilution risk upon conversion of 5.41 Cr warrants into equity shares.
- Subject to shareholder and statutory/regulatory approvals.
- Full receipt of funds is contingent on warrant conversion over up to 18 months.
Key Highlights
Proposed preferential issue of up to 5,41,12,553 fully convertible warrants convertible 1:1 into equity shares.
Minimum issue price/floor price determined at ₹2.31 per warrant (face value ₹1 each).
Total aggregate fundraise consideration proposed at ₹12,49,99,997 (~₹12.50 Cr).
Pricing established based on the Relevant Date of August 25, 2026 under SEBI ICDR Regulations.
👀 What to Watch
Track shareholder meeting dates for voting approval, disclosure of specific allottees, and timelines for warrant subscription and conversion.
HOMRE Board Approves ₹12.50 Cr Preferential Warrants Issue and 3 Cr ESOP Scheme
HOMRE Ltd's Board has approved raising up to ₹12.50 crore via a preferential issue of fully convertible warrants to 8 investors across promoter and non-promoter groups. The fundraise represents approximately 27.8% of the company's current market capitalization of ₹45 crore. Additionally, the Board approved the introduction of HOMRE ESOP 2026 covering up to 3,00,00,000 equity options. Both proposals are subject to shareholder approval at the upcoming 36th AGM scheduled for September 24, 2026.
Confidence: HIGH
What changedThe Board approved a ₹12.50 crore capital raise via preferential warrants and created a 3-crore share ESOP pool, pending shareholder approval.
Why it mattersA ₹12.50 crore capital infusion represents over 46% of TTM revenue (₹27 Cr) and about 28% of market cap (₹45 Cr), significantly enhancing the balance sheet while bringing equity dilution over the next 18 months.
Warrant Issue Size: ₹12,50,00,000Issue Size vs Market Cap: ~27.8%Issue Size vs TTM Revenue: ~46.3%ESOP Pool Size: 3,00,00,000 optionsRelevant Date: August 25, 2026AGM Date: September 24, 2026
📅 Short termMarket focus will be on the pricing formula outcome on the August 25 relevant date and shareholder approval at the September 24 AGM.
📈 Long termIf successfully converted over 18 months, the funds will inject equity capital into the micro-cap business, though existing equity holders will face dilution from both the warrants and the 3 crore ESOP pool.
⚠ Risk flags
- Equity dilution for existing public shareholders upon warrant conversion and ESOP exercise
- Conversion timeline spans up to 18 months, meaning cash inflows could be staggered
Key Highlights
Preferential issue of fully convertible warrants for an aggregate consideration of up to ₹12,50,00,000
Approval of HOMRE ESOP 2026 covering up to 3,00,00,000 equity options of face value ₹1 each
Proposed allotment to 8 investors, including promoter entity Supriya Securities Pvt. Ltd. (holding to rise from 0.81% to 8.45%) and Ganpati Warehousing Ltd (0.06% to 11.78%)
Relevant date for warrant pricing fixed as August 25, 2026, with an 18-month conversion window
36th Annual General Meeting convened for September 24, 2026
👀 What to Watch
Track the determination of the final issue price based on the August 25, 2026 relevant date and monitor shareholder voting results at the September 24, 2026 AGM.
Aug 19 Board Meeting to Consider Preferential Issue of Warrants and ESOP 2026
HOMRE Ltd has scheduled a board meeting on August 19, 2026, to consider a preferential issue of fully convertible warrants to promoters and non-promoters. This capital-raising move is significant given the company's current financial position, featuring a high debt-to-equity ratio of 10.21 and a net worth of approximately ₹0 Cr. The board will also discuss the implementation of a new Employee Stock Option Plan (ESOP 2026) and approve the notice for the upcoming Annual General Meeting. Investors should note that while the fundraise could provide liquidity, it will lead to equity dilution.
Confidence: HIGH
What changedThe company is initiating a formal process to raise capital through convertible warrants and introduce an employee stock option scheme.
Why it mattersFor a micro-cap company with zero net worth and high debt, a preferential issue is a critical step for balance sheet repair or funding operations, though it comes at the cost of shareholder dilution.
Board Meeting Date: August 19, 2026Market Cap: ₹36 CrDebt-to-Equity Ratio: 10.21TTM Revenue: ₹15 CrNet Worth: ₹0 Cr
📅 Short termThe stock may see volatility leading up to and following the August 19 meeting as investors speculate on the warrant pricing and the profile of new investors.
📈 Long termThe long-term impact depends on whether the capital raised is used to reduce debt or fund growth, and the extent of dilution caused by the ESOP and warrant conversions.
⚠ Risk flags
- Equity dilution from warrants and ESOPs
- Extremely high leverage (D/E 10.21)
- Stressed balance sheet with zero net worth
Key Highlights
Board meeting scheduled for August 19, 2026, to approve capital raising via warrants.
Proposal includes a new 'ESOP 2026' plan for employee compensation.
Company currently operates with a high Debt-to-Equity ratio of 10.21.
TTM Revenue is ₹15 Cr against a small Market Cap of ₹36 Cr.
Promoter holding has seen a slight decline from 67.62% in June 2025 to 65.73% in March 2026.
👀 What to Watch
Monitor the outcome of the August 19 board meeting for specific details on the issue price, the total amount to be raised, and the identity of the non-promoter investors.
HOMRE Ltd Appoints 2 New Independent Directors and Re-designates Board; ED Resigns
HOMRE Ltd (formerly Triton Corp) has announced a significant board restructuring, appointing Mr. Ashok Chopra and Mrs. Puneeta K Sharma as Independent Directors for one-year terms effective July 23, 2026. Additionally, two existing directors were re-designated as Independent, while Executive Director Mr. Sachin Kumar Bhimrajka resigned effective June 22, 2026. These changes occur as the company manages a high debt-to-equity ratio of 10.21 and a market cap of just Rs 39 Cr. The board also approved Q1 FY27 results, noting a minor loss of Rs 0.02 lacs in its subsidiary, Maple Solutions Limited.
Confidence: HIGH
What changedThe company has overhauled its board by adding two new independent members and losing one executive director, while shifting two other members to independent status.
Why it mattersFor a micro-cap company with zero net worth and high debt, board independence and governance are critical for potential recovery or strategic pivots.
Market Cap: Rs 39 CrDebt: Rs 3 CrDebt/Equity Ratio: 10.21Subsidiary Q1 Loss: Rs 0.02 lacsDirector Appointment Term: 1 year
📅 Short termThe management changes are unlikely to impact the stock price significantly in the short term, as the market will focus more on the underlying financial health and Q1 results.
📈 Long termThe shift toward a more independent board is structurally positive for governance, but the company's long-term viability depends on addressing its zero net worth and high debt levels.
⚠ Risk flags
- High Debt-to-Equity ratio (10.21)
- Zero Net Worth
- Resignation of an Executive Director
- Short 1-year tenure for new independent directors
Key Highlights
Appointment of 2 new Independent Directors for a 1-year term effective July 23, 2026
Resignation of Executive Director Mr. Sachin Kumar Bhimrajka effective June 22, 2026
Re-designation of 2 Non-Independent Directors to Independent status effective June 23, 2026
Subsidiary Maple Solutions Limited reported a net loss of Rs 0.02 lacs for the quarter ended June 30, 2026
Company continues to operate with a high Debt/Equity ratio of 10.21 and zero net worth
👀 What to Watch
Investors should monitor the full Q1 FY27 financial results to assess if the new board composition leads to improved operational performance or debt restructuring, given the company's current financial fragility.
HOMRE Ltd Q1 FY27 Results: Subsidiary Reports NIL Revenue Amid Major Board Overhaul
HOMRE Ltd (formerly Triton Corp) approved its Q1 FY27 results, showing its 100% subsidiary, Maple Solutions Limited, generated zero revenue and a nominal loss of Rs 0.02 lacs. The company is undergoing a significant board restructuring, including the resignation of an Executive Director and the appointment of two new Independent Directors. With a market cap of only Rs 39 Cr and a high debt-to-equity ratio of 10.21, the company remains in a precarious financial position with zero net worth as per recent context.
Confidence: MEDIUM
What changedThe company approved its quarterly financial results and significantly restructured its board by adding independent oversight and accepting an executive resignation.
Why it mattersFor a micro-cap company with high leverage (D/E 10.21) and zero net worth, governance changes and the performance of subsidiaries are critical indicators of potential turnaround or further distress.
Subsidiary Revenue: NILSubsidiary Net Loss: Rs 0.02 lacsDebt-to-Equity Ratio: 10.21Market Cap: Rs 39 CrPromoter Holding: 65.73%
📅 Short termThe stock may remain volatile due to its micro-cap nature; the board changes are administrative and unlikely to drive immediate price action without a strong P&L surprise.
📈 Long termLimited structural significance unless the new board can address the negative net worth and high debt levels through a clear business strategy.
⚠ Risk flags
- High Debt-to-Equity (10.21)
- Zero Net Worth
- Micro-cap liquidity risks
- Executive Director resignation
Key Highlights
Subsidiary Maple Solutions Limited reported NIL revenue for the quarter ended June 30, 2026
Subsidiary net loss stood at a nominal Rs 0.02 lacs for the quarter
Executive Director Mr. Sachin Kumar Bhimrajka resigned effective June 22, 2026
Two new Independent Directors, Mr. Ashok Chopra and Mrs. Puneeta K Sharma, appointed for 1-year terms
Two existing directors transitioned from Non-Independent to Independent status effective June 23, 2026
👀 What to Watch
Investors should monitor the full standalone P&L statement to see if the company can sustain the revenue growth seen in the previous two quarters (Mar 2026: Rs 5.96 Cr) given the current zero net worth status.
HOMRE Ltd Appoints 2 New Directors and Approves Q1 FY27 Results; Executive Director Resigns
HOMRE Ltd (formerly Triton Corp) held a board meeting on July 23, 2026, to approve its Q1 FY27 unaudited financial results and overhaul its board structure. The company appointed two new Independent Directors, Mr. Ashok Chopra and Mrs. Puneeta K Sharma, for one-year terms. Additionally, two existing directors were re-designated as Independent, while Executive Director Sachin Kumar Bhimrajka resigned effective June 22, 2026. Financially, its 100% subsidiary, Maple Solutions Limited, reported zero revenue and a marginal loss of Rs 0.02 lacs for the quarter.
Confidence: HIGH
What changedThe company has significantly restructured its board by adding new independent oversight and accepting the resignation of an executive director, alongside approving its first-quarter results for the new fiscal year.
Why it mattersFor a micro-cap company with a market cap of only Rs 39 Cr and a high debt-to-equity ratio, changes in board governance and the performance of subsidiaries are key indicators of management stability and fiscal health.
Subsidiary Revenue (Q1 FY27): NILSubsidiary Net Loss (Q1 FY27): Rs 0.02 lacsDebt-to-Equity Ratio: 10.21Market Capitalization: Rs 39 Cr
📅 Short termThe stock is likely to remain neutral in the short term as the board changes are administrative and the subsidiary's financial impact is negligible.
📈 Long termThe long-term outlook depends on the company's ability to leverage its new board expertise to scale operations beyond its current TTM revenue of Rs 15 Cr and manage its high debt levels.
⚠ Risk flags
- High Debt-to-Equity ratio (10.21)
- Resignation of an Executive Director
- Zero revenue from 100% subsidiary Maple Solutions Limited
- Negative Net Worth (Rs 0 Cr)
Key Highlights
Appointment of 2 new Independent Directors, Mr. Ashok Chopra and Mrs. Puneeta K Sharma, effective July 23, 2026
Resignation of Executive Director Mr. Sachin Kumar Bhimrajka effective from the closing hours of June 22, 2026
Subsidiary Maple Solutions Limited reported a net loss of Rs 0.02 lacs on NIL revenue for Q1 FY27
Two directors, Mr. Rohit Inder Himatsingani and Mr. Abhishek Bhagwat Bharad, re-designated as Independent Directors
Board meeting duration was approximately 2 hours and 50 minutes, concluding at 5:50 P.M.
👀 What to Watch
Investors should review the detailed Q1 FY27 financial results once fully published to assess if the company can improve its OPM (4.7%) and address its high Debt-to-Equity ratio of 10.21.
